Microbot Medical (NASDAQ:MBOT – Get Free Report) and ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.
Volatility and Risk
Microbot Medical has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.
Profitability
This table compares Microbot Medical and ClearPoint Neuro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Microbot Medical | N/A | -76.27% | -67.54% |
| ClearPoint Neuro | -66.15% | -94.44% | -51.58% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Microbot Medical | 0 | 0 | 1 | 0 | 3.00 |
| ClearPoint Neuro | 0 | 0 | 3 | 0 | 3.00 |
Microbot Medical currently has a consensus target price of $9.00, indicating a potential upside of 191.26%. ClearPoint Neuro has a consensus target price of $19.6667, indicating a potential upside of 88.02%. Given Microbot Medical’s higher probable upside, analysts plainly believe Microbot Medical is more favorable than ClearPoint Neuro.
Institutional & Insider Ownership
16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Comparatively, 6.1% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Microbot Medical and ClearPoint Neuro”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Microbot Medical | N/A | N/A | -$11.44 million | ($0.58) | -5.33 |
| ClearPoint Neuro | $31.39 million | 9.47 | -$18.91 million | ($0.81) | -12.91 |
Microbot Medical has higher earnings, but lower revenue than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Summary
Microbot Medical beats ClearPoint Neuro on 7 of the 12 factors compared between the two stocks.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
